Arizona State Retirement System Sells 4,548 Shares of IQVIA Holdings Inc. $IQV

Arizona State Retirement System reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 8.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,683 shares of the medical research company’s stock after selling 4,548 shares during the quarter. Arizona State Retirement System’s holdings in IQVIA were worth $10,523,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alliancebernstein L.P. lifted its position in IQVIA by 1.2% in the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after purchasing an additional 41,643 shares during the period. Boston Partners bought a new position in IQVIA in the third quarter worth $676,698,000. Artisan Partners Limited Partnership lifted its position in IQVIA by 4.9% in the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock worth $652,246,000 after purchasing an additional 161,085 shares during the period. Invesco Ltd. raised its stake in IQVIA by 15.3% during the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after acquiring an additional 367,204 shares in the last quarter. Finally, Nordea Investment Management AB raised its stake in IQVIA by 12.3% during the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock worth $421,257,000 after acquiring an additional 253,759 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $162.48 on Friday. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The firm has a market cap of $27.57 billion, a PE ratio of 20.67, a price-to-earnings-growth ratio of 1.60 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The business has a fifty day moving average of $170.03 and a 200-day moving average of $202.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 11.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on IQV shares. Truist Financial dropped their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research note on Tuesday. Royal Bank Of Canada started coverage on IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective for the company. Finally, Jefferies Financial Group dropped their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $226.63.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.